Author: Fratta Pasini, Anna M.; Stranieri, Chiara; Cominacini, Luciano; Mozzini, Chiara
Title: Potential Role of Antioxidant and Anti-Inflammatory Therapies to Prevent Severe SARS-Cov-2 Complications Cord-id: 6cqzeni5 Document date: 2021_2_10
ID: 6cqzeni5
Snippet: The coronavirus disease 2019 (COVID-19) pandemic is caused by a novel severe acute respiratory syndrome (SARS)-like coronavirus (SARS-CoV-2). Here, we review the molecular pathogenesis of SARS-CoV-2 and its relationship with oxidative stress (OS) and inflammation. Furthermore, we analyze the potential role of antioxidant and anti-inflammatory therapies to prevent severe complications. OS has a potential key role in the COVID-19 pathogenesis by triggering the NOD-like receptor family pyrin domain
Document: The coronavirus disease 2019 (COVID-19) pandemic is caused by a novel severe acute respiratory syndrome (SARS)-like coronavirus (SARS-CoV-2). Here, we review the molecular pathogenesis of SARS-CoV-2 and its relationship with oxidative stress (OS) and inflammation. Furthermore, we analyze the potential role of antioxidant and anti-inflammatory therapies to prevent severe complications. OS has a potential key role in the COVID-19 pathogenesis by triggering the NOD-like receptor family pyrin domain containing 3 inflammasome and nuclear factor-kB (NF-kB). While exposure to many pro-oxidants usually induces nuclear factor erythroid 2 p45-related factor2 (NRF2) activation and upregulation of antioxidant related elements expression, respiratory viral infections often inhibit NRF2 and/or activate NF-kB pathways, resulting in inflammation and oxidative injury. Hence, the use of radical scavengers like N-acetylcysteine and vitamin C, as well as of steroids and inflammasome inhibitors, has been proposed. The NRF2 pathway has been shown to be suppressed in severe SARS-CoV-2 patients. Pharmacological NRF2 inducers have been reported to inhibit SARS-CoV-2 replication, the inflammatory response, and transmembrane protease serine 2 activation, which for the entry of SARS-CoV-2 into the host cells through the angiotensin converting enzyme 2 receptor. Thus, NRF2 activation may represent a potential path out of the woods in COVID-19 pandemic.
Search related documents:
Co phrase search for related documents- access receptor and adjuvant therapy: 1
- access receptor and adjuvant treatment: 1
- accessory protein and activator protein: 1
- accessory protein and activity suppression: 1
- accessory protein and acute lung injury: 1
- accessory protein and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- ace counterbalance and acute respiratory syndrome: 1
- activate neutrophil and acute lung injury: 1
- activate neutrophil and acute respiratory syndrome: 1, 2
- activator protein and acute lung injury: 1, 2, 3, 4
- activator protein and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- activator protein and adjuvant therapy: 1
- activator protein and adjuvant treatment: 1
- activity suppression and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- acute lung injury and adenine nadph dinucleotide phosphate: 1
- acute lung injury and adjuvant therapy: 1, 2, 3, 4
- acute lung injury and adjuvant treatment: 1, 2
- acute lung injury and administration day: 1, 2
- acute respiratory syndrome and adenine nadph dinucleotide phosphate: 1
Co phrase search for related documents, hyperlinks ordered by date